Neurosteer’s Peer-Reviewed Publication: Evaluation of Parkinson’s Disease Early Diagnosis with Neurosteer’s hdrEEG™ System
Neurosteer’s Peer-Reviewed Publication: Evaluation of Parkinson’s Disease Early Diagnosis with Neurosteer’s hdrEEG™ System
NEW YORK, Dec. 19, 2023 -- Neurosteer Inc. announces the publication of our groundbreaking paper in Frontiers in Neurology detailing a revolutionary approach to Parkinson's disease detection and differentiation using our pocket-sized hdrEEG™ system and a rapid 15-minute auditory assessment.disorders.
The study was performed using Neurosteer’s FDA cleared medical-grade hdrEEG™ system which represents a breakthrough in brain “scanning” and offers a completely novel approach to analyzing brain activity.
The system is designed to support early detection and differentiation of neurodegenerative disorders and continuous brain monitoring in the ICU.disorders.
Neurosteer’s wireless, pocket-sized, medical-grade wearable device, with its innovative forehead-attached electrode adhesive strip, can be used anywhere. It is low cost, massively deployable, automatic and objective.
In conjunction with the device, our noninvasive, 15-minute auditory brain health assessment was used in the study for the detection of Parkinson's disease.
Paired with our cloud-based signal processing server, our system showed excellent correlation to F-DOPA PET scans in detecting and differentiating Parkinson’s disease, for a fraction of the cost, in a simple to operate, noninvasive, 15 minute procedure that can be performed virtually anywhere.
By contrast, today’s Parkinson’s disease assessments using F-DOPA PET scanners are invasive, cumbersome, and extremely expensive, and require a dedicated facility and subjective interpretation by clinicians. As a result, they are only performed after the onset of symptoms, by which time it may be too late for effective treatment.
Preliminary data suggests similar promise for Alzheimer’s disease, making it ideal for patient screening to benefit from recent Alzheimer’s drugs.
The company intends to establish a new standard of care in brain assessment and revolutionize early detection of Parkinson’s, Alzheimer’s and other neurodegenerative disorders.
